Patents by Inventor Joyson J. Karakunnel

Joyson J. Karakunnel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING WITH AN AZOLOPYRIMIDINE COMPOUND
    Publication number: 20230338377
    Abstract: Provided herein are methods of treating a disease, disorder, or condition, mediated at least in part by the adenosine A2A receptor (A2AR) and/or the adenosine A2B receptor (A2BR) using Compound (I). In some embodiments, the disease or disorder is a cancer related disorder. Also provided herein are pharmaceutical compositions and single unit dosages of Compound (I).
    Type: Application
    Filed: March 23, 2023
    Publication date: October 26, 2023
    Inventor: Joyson J. Karakunnel
  • PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS
    Publication number: 20200405629
    Abstract: Methods of identifying compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and that possess particular pharmacokinetic characteristics are described herein. Methods of such compounds, and compositions comprising same, for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, are also provided.
    Type: Application
    Filed: March 8, 2019
    Publication date: December 31, 2020
    Inventors: Juan Carlos JAEN, Jenna Leigh JEFFREY, Lixia JIN, Jaroslaw KALISIAK, Joyson J. KARAKUNNEL, M.D., Kenneth V. LAWSON, Manmohan Reddy LELETI, Jay Patrick POWERS
  • COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION
    Publication number: 20200171149
    Abstract: The present invention features methods of treating lung cancer (e.g., NSCLC) with an anti-PD-L1 antibody and a tyrosine kinase inhibitor in a subject identified as having an EGFR mutation-positive tumor.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 4, 2020
    Inventors: MOHAMMED M. DAR, JOYSON J. KARAKUNNEL, HAIYI JIANG, MAXWELL J. KIRKBY
  • COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION
    Publication number: 20180147279
    Abstract: The present invention features methods of treating lung cancer (e.g., NSCLC) with an anti-PD-L1 antibody and a tyrosine kinase inhibitor in a subject identified as having an EGFR mutation-positive tumor.
    Type: Application
    Filed: April 22, 2016
    Publication date: May 31, 2018
    Inventors: Mohammed M. DAR, Joyson J. KARAKUNNEL, Haiyi JIANG, Maxwell J. KIRKBY
  • COMBINATION THERAPY FOR PD-L1 NEGATIVE TUMORS
    Publication number: 20160060344
    Abstract: The present invention features methods of treating lung cancer (e.g., NSCLC) with an anti-PD-L1 antibody and tremelimumab in a subject identified as having a PD-L1 negative tumor.
    Type: Application
    Filed: August 28, 2015
    Publication date: March 3, 2016
    Inventors: Rajesh Narwal, Marlon C. Rebelatto, Keith Steele, Paul Robbins, Ross Anthony Stewart, John A. Blake-Haskins, Joyson J. Karakunnel, Ramy Ibrahim, Aiman Shalabi, Alessandra Di Pietro, Li Shi, Shengyan Hong, Paul Stockman, Marc Ballas, Mohammed M. Dar